Notice2022-01329

National Cancer Institute; Notice of Meeting

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
January 25, 2022

Issuing agencies

Health and Human Services DepartmentNational Institutes of Health

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 16 (Tuesday, January 25, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 16 (Tuesday, January 25, 2022)]
[Notices]
[Page 3830]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-01329]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Cancer 
Institute Clinical Trials and Translational Research Advisory 
Committee.
    The meeting will be held as a virtual meeting and is open to the 
public. Individuals who plan to view the virtual meeting and need 
special assistance or other reasonable accommodations to view the 
meeting, should notify the Contact Person listed below in advance of 
the meeting. The meeting will be videocast and can be accessed from the 
NIH Videocasting and Podcasting website (<a href="http://videocast.nih.gov">http://videocast.nih.gov</a>).

    Name of Committee: National Cancer Institute Clinical Trials and 
Translational Research Advisory Committee.
    Date: March 16, 2022.
    Time: 12:00 p.m. to 3:00 p.m.
    Agenda: Strategic Discussion of NCI's Clinical and Translational 
Research Programs.
    Place: National Cancer Institute, 9609 Medical Center Drive, 
Rockville, MD 20850 (Virtual Meeting).
    Contact Person: Sheila A. Prindiville, M.D., M.P.H., Director, 
Coordinating Center for Clinical Trials, National Cancer Institute, 
National Institutes of Health, 9609 Medical Center Drive, Room 
6W136, Rockville, MD 20850, 240-276-6173, <a href="/cdn-cgi/l/email-protection#0373716a6d676a7570436e626a6f2d6d6a6b2d646c75"><span class="__cf_email__" data-cfemail="d2a2a0bbbcb6bba4a192bfb3bbbefcbcbbbafcb5bda4">[email&#160;protected]</span></a>.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: <a href="http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm">http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm</a>, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: January 19, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-01329 Filed 1-24-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on January 25, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.